Abstract
OBJECTIVE: Since 2010, gemcitabine and cisplatin have been considered standard first-line treatment in patients with advanced biliary tract cancer. Many centers have replaced cisplatin with oxaliplatin, which seems to obtain similar results. While first-line treatment has been well established, there are no phase III trials supporting second-line treatment, and the phase II trials with chemotherapy do not show any clear benefit. In this study, we investigated the effect of adding bevacizumab to chemotherapy in second-line treatment.
METHODS: From November 2013 to January 2016, 50 patients with advanced biliary tract cancer were enrolled in this prospective phase II trial. All patients had received a gemcitabine-platinum combination as first-line treatment. The patients received capecitabine, irinotecan, gemcitabine, and bevacizumab in a 2-week schedule as second-line treatment.
RESULTS: The combination was well tolerated with a median progression-free survival of 3.6 months, a median overall survival of 6.4 months, and a response rate of 6%.
CONCLUSION: The combination of capecitabine, irinotecan, gemcitabine, and bevacizumab as a second-line treatment for advanced biliary tract cancer is well tolerated but with a modest, if any, benefit.
| Original language | English |
|---|---|
| Journal | Oncology |
| Volume | 94 |
| Issue number | 1 |
| Pages (from-to) | 19-24 |
| ISSN | 0030-2414 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Bevacizumab/administration & dosage
- Biliary Tract Neoplasms/drug therapy
- Camptothecin/administration & dosage
- Capecitabine/administration & dosage
- Deoxycytidine/administration & dosage
- Disease-Free Survival
- Female
- Humans
- Irinotecan
- Male
- Middle Aged
- Organoplatinum Compounds/administration & dosage
- Prospective Studies
